Emerging therapies in Friedreich’s Ataxia-Reference-Cited by-同舟云学术

Emerging therapies in Friedreich’s Ataxia

Published:2020-09-21 Issue:12 Volume:20 Page:1215-1228
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Zesiewicz Theresa A.¹,Hancock Joshua¹,Ghanekar Shaila D.¹,Kuo Sheng-Han²³,Dohse Carlos A.⁴,Vega Joshua¹

Affiliation:

1. University of South Florida (USF) Department of Neurology, USF Ataxia Research Center, Tampa Florida, James A Haley Veteran’s Hospital, Tampa, Florida, USA

2. Department of Neurology, Columbia University, New York, NY, USA

3. Initiative for Columbia Ataxia and Tremor, New York, NY, USA

4. Universidad Central Del Caribe School of Medicine, Bayamon, Puerto Rico

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Clinical Neurology,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2020.1821654

Reference102 articles.

1. Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion

2. Ataxias

3. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in the Treatment Strategies of Friedreich’s Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms;Current Pharmaceutical Design;2024-05

2. Standing Balance Conditions and Digital Sway Measures for Clinical Trials of Friedreich's Ataxia;Movement Disorders;2024-03-12

3. The Optic Nerve at Stake: Update on Environmental Factors Modulating Expression of Leber’s Hereditary Optic Neuropathy;Biomedicines;2024-03-06

4. Nerve ultrasound in Friedreich’s Ataxia: enlarged nerves as a biomarker of disease severity;Clinical Neurophysiology;2024-03

5. Evaluating the therapeutic efficacy of SKYCLARYS: a promising FDA-approved drug for Friedreich ataxia treatment;International Journal of Surgery: Global Health;2024-01